A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

2025-521052-35-00 Protocol ARI-HER2 Phase I and Phase II (Integrated) - First administration to humans Not authorised

Status Not authorised · 1 EU/EEA countries · 3 sites · Protocol ARI-HER2

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Not authorised
Participants planned 18
Countries 1
Sites 3

Patients with HER2Positive Advanced Breast Cancer

Key facts

Sponsor
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04], Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01], Phenomena and Processes [G] - Immune system processes [G12], Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02], Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
Decision date (initial)
2025-10-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with HER2Positive Advanced Breast Cancer

VersionLevelCodeTermSystem organ class
21.1 LLT 10072737 Advanced breast cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Sponsor organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Address
Calle Rosellon 149-153
City
Barcelona
Postcode
08036
Country
Spain

Scientific contact point

Organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Contact name
Laura Angelats

Public contact point

Organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Contact name
Laura Angelats

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Not authorised 18 3
Rest of world 0

Investigational sites

Spain

3 sites · Not authorised
Clinica Universidad De Navarra
Oncology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Clinic De Barcelona
Oncology, Calle Rosellon 138, 08036, Barcelona
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-06-10 Spain Not acceptable
2025-10-14
2025-10-15